TFX logo

TELEFLEX INC

TFXNYSE
πŸ† #1137 by market capEarnings Nov 5 Β· PreUS Equity
$138.98β–Ό $0.01 (βˆ’0.01%)
Market closed Β· at close
πŸ””
Track TFX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.0%
7dβ–² 1.5%
14dβ–² 8.4%
30dβ–² 9.9%
ytdβ–² 13.8%
1yβ–² 8.3%
🏦Market Cap
$5.89B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-14.5%
Declining
πŸ“ŠGross Margin
53.8%
Healthy
πŸ’΅FCF Margin
13.1%
Healthy
βš–οΈP/S Ratio
2.2x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
$136.92 – $140.01
52-Week Range
$100.18 – $145.00
Volume (shares)
630,141
Avg Volume (shares)
β€”
Shares Outstanding
42.4M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$1.99B
Last Q Revenue
$570M
P/E Ratio
β€”
P/S Ratio
2.2x
EPS (TTM)
$-23.29
Dividend Yield
1.03%
Dilution (1yr)
βˆ’4.6%
TFX logo

TELEFLEX INC

TFX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.0Bβ–Ό βˆ’34.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
56.2%β–² +0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$256Mβ–² +69.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$245Mβ–Ό βˆ’51.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
44.2Mβ–Ό βˆ’4.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.3Bβ–Ό βˆ’$868M YoY
StockOtter Β· stockotter.space

About TELEFLEX INC

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

Business WireΒ·7d ago

Teleflex Announces FDA Breakthrough Device Designation for Freesolveβ„’ Resorbable Magnesium Scaffold

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designat

Business WireΒ·7d ago

Teleflex Announces Third Quarter 2026 Earnings Conference Call Information

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5

Business WireΒ·17d ago

Enrollment Completed in BIOMAGβ„’-LL Clinical Study Evaluating Longer Lengths for Freesolveβ„’ Resorbable Magnesium Scaffold

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAGβ„’-LL Clinical Study, evaluat

Zacks Investment ResearchΒ·22d ago

TFX or SONVY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment ResearchΒ·22d ago

Is It Prudent to Add Teleflex Stock to Your Portfolio Now?

TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.

Business WireΒ·Sep 29

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ardβ„’ Technology

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Co